Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BCYC with free AI briefings, catalyst countdowns, and dilution alerts.

BCYC · Bicycle Therapeutics plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$469.9M Cash on Hand
31.4mo Cash Runway
Follow BCYC by email Get an email when BCYC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BCYC, unsubscribe in one click. Privacy

📣 What BCYC Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Naloxone Opioid Use Disorder Phase 4 · NCT05644587 Terminated
BT1718 Advanced Solid Tumours Phase 1/2 · NCT03486730 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BCYC holds $469.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $45M/quarter from operations, an estimated runway of 31.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 10 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BCYC files for a raise →

👥 Who Owns BCYC

Insiders 38.6% Institutions (124 holders) 61.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
BAKER BROS. ADVISORS LP
Director, 10% owner · +38,000 options
Insider 10,018,674 33.35% 2026-01-02
Armistice Capital, LLC Institution (13G, 5%+) 3,472,000 11.56% 2026-09-30
LONG FOCUS CAPITAL MANAGEMENT, LLC Institution (13G, 5%+) 3,310,687 11.02% 2026-03-31
Kevin Lee
CHIEF EXECUTIVE OFFICER, Director · +330,000 options
Insider 595,866 1.98% 2026-10-02
Gregory Paul Winter
Director · +19,000 options
Insider 196,427 0.65% 2026-01-02
Michael Skynner
CHIEF SCIENTIFIC OFFICER · +160,000 options
Insider 154,726 0.52% 2026-10-02
Alistair Milnes
CHIEF OPERATING OFFICER · +100,000 options
Insider 136,717 0.46% 2026-01-02
Michael Charles Ferguson Hannay
CHIEF PROD & SUPPLY CHAIN OFF · +160,000 options
Insider 92,561 0.31% 2026-10-02
Jennifer Scott Perry
Chief Operating Officer · +60,000 options
Insider 89,602 0.30% 2026-10-02
Alethia Young
Chief Financial Officer · +100,000 options
Insider 87,081 0.29% 2026-01-02
Travis Alvin Thompson
Chief Financial Officer · +193,000 options
Insider 64,449 0.21% 2026-10-02
Janice Bourque
Director · +19,000 options
Insider 32,500 0.11% 2026-01-02

Share count 30,043,486 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BCYC picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BCYC and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.